

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/T9DCC81133CEN.html>

Date: July 2018

Pages: 87

Price: US\$ 3,500.00 (Single User License)

ID: T9DCC81133CEN

Abstracts

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2018

SUMMARY

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 26 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal

center formation.

The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 8, 7 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Genito Urinary System And Sex Hormones, Central Nervous System, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Gastric Cancer, Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Kidney Transplant Rejection, Lymphoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Ovarian Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Crohn's Disease (Regional Enteritis), Head And Neck Cancer Squamous Cell Carcinoma, Lupus Nephritis, Malignant Mesothelioma, Adenocarcinoma Of The Gastroesophageal Junction, Anaplastic Astrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Central Nervous System (CNS) Tumor, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Esophageal Cancer, Focal Segmental Glomerulosclerosis (FSGS), Follicular Lymphoma, Gastroesophageal (GE) Junction Carcinomas, Glioblastoma Multiforme (GBM), Glioma, Gliosarcoma, Graves Diseases, Head And Neck Cancer, Heart Transplant Rejection, Hepatic (Liver) Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hyperthyroidism, Kidney Cancer (Renal Cell Cancer), Liver Transplant Rejection, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Myasthenia Gravis, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Transplant Rejection, Pediatric Diffuse Intrinsic Pontine Glioma, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases

from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)

The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects

The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development

AbbVie Inc

Apexigen Inc

Apogenix AG

BioNTech AG

Boehringer Ingelheim GmbH

Celldex Therapeutics Inc

Denceptor Therapeutics Ltd

F. Hoffmann-La Roche Ltd

Johnson & Johnson

Kyowa Hakko Kirin Co Ltd

MedImmune LLC

Novartis AG

Seattle Genetics Inc

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles

2C-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABBV-428 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABBV-927 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APG-1233 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-005M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-655064 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Agonize CD40 and 4-1BB for Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bleselumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-1140 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ChiLob-7/4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNP-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emactuzumab + selicrelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FFP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-7107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KGYY-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-5083 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MegaCD40L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize CD40 and Antagonize FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugate to Target CD40 for Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SEA-CD40 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selicrelumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

selicrelumab + vanucizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UltraCD40L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones

Featured News & Press Releases

May 18, 2018: Apexigen Expands Leadership Team with Appointment of Frances Rena Bahjat, Vice President, Discovery Research

May 17, 2018: Seattle Genetics Announces Data Presentation on SEA-CD40 at 2018 ASCO Annual Meeting

Apr 20, 2018: Celldex Therapeutics presents data on CDX-1140 at AACR Annual Meeting 2018

Jan 03, 2018: Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013

Nov 30, 2017: Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors

Nov 07, 2017: Results from Alligator Biosciences clinical phase I study support further clinical development of ADC-1013

Oct 31, 2017: Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer Annual Meeting

Oct 25, 2017: Apexigen Announces New Collaboration with UCSF

Sep 21, 2017: Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017

Sep 20, 2017: The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy

Jul 17, 2017: Apexigen Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors

May 10, 2017: Boehringer Ingelheim Phase II trial Now Enrolling Patients with the Kidney Disease Lupus Nephritis

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ADC-1013

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ADC-1013 at PEGS conference in Boston, May

Apr 03, 2017: Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Products under Development by Companies, H2 2018 (Contd.4), H2 2018
Products under Development by Companies, H2 2018 (Contd.5), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AbbVie Inc, H2 2018
Pipeline by Apexigen Inc, H2 2018
Pipeline by Apogenix AG, H2 2018
Pipeline by BioNTech AG, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Celldex Therapeutics Inc, H2 2018
Pipeline by Denceptor Therapeutics Ltd, H2 2018
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Seattle Genetics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

AbbVie Inc
Apexigen Inc
Apogenix AG
BioNTech AG
Boehringer Ingelheim GmbH
Celldex Therapeutics Inc
Denceptor Therapeutics Ltd
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Kyowa Hakko Kirin Co Ltd
MedImmune LLC
Novartis AG
Seattle Genetics Inc

I would like to order

Product name: Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/T9DCC81133CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T9DCC81133CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

